Targeting DNA double-strand break repair pathways to improve radiotherapy response
M Toulany - Genes, 2019 - mdpi.com
More than half of cancer patients receive radiotherapy as a part of their cancer treatment.
DNA double-strand breaks (DSBs) are considered as the most lethal form of DNA damage …
DNA double-strand breaks (DSBs) are considered as the most lethal form of DNA damage …
Locally advanced, unresectable non-small cell lung cancer
Abstract Purpose of Review Treatment of locally advanced, unresectable non-small cell lung
cancer (NSCLC) has recently been revolutionized by the incorporation of immunotherapy to …
cancer (NSCLC) has recently been revolutionized by the incorporation of immunotherapy to …
Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small cell lung cancer
R Komaki, PK Allen, X Wei, GR Blumenschein… - International Journal of …, 2015 - Elsevier
Purpose To test, in a single-arm, prospective, phase 2 trial, whether adding the epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to concurrent …
growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to concurrent …
[HTML][HTML] Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer
N Wang, L Wang, X Meng, J Wang… - Oncology …, 2019 - spandidos-publications.com
Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with …
tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with …
Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiation Therapy in Patients With Non-Small Cell Lung Cancer: A Systematic …
Y Meng, H Sun, S Wang, H Yang - International Journal of Radiation …, 2023 - Elsevier
Thoracic radiation therapy (RT) for non-small cell lung cancers may overcome resistance to
tyrosine kinase inhibitors (TKIs). However, the risk of severe treatment-related pneumonitis …
tyrosine kinase inhibitors (TKIs). However, the risk of severe treatment-related pneumonitis …
Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer—How to Identify Patients Which Can Benefit from It?
B Jeremić, E Mariamidze, I Shoshiashvili, I Kiladze - Current Oncology, 2022 - mdpi.com
Background: Consolidation systemic therapy (ST) given after concurrent radiotherapy (RT)
and ST (RT-ST) is frequently practiced in locally advanced inoperable nonsmall cell lung …
and ST (RT-ST) is frequently practiced in locally advanced inoperable nonsmall cell lung …
Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer
D Marquez-Medina, S Popat - Future Oncology, 2016 - Future Medicine
Nonadvanced non-small-cell lung cancer (NSCLC) has a poor long-term survival from
surgery or definitive radiation that is minimally improved with induction/adjuvant …
surgery or definitive radiation that is minimally improved with induction/adjuvant …
EGFR—TKI 在局部晚期非小细胞肺癌中的应用
吴霞， 冯国生 - 国际肿瘤学杂志, 2016 - cqvip.com
随着肺癌分子生物学研究的不断深入, 小分子靶点类抗肿瘤药物取得了突破性的进展,
表皮生长因子受体酪氨酸激酶抑制剂(EGFR—TKI) 是其中最受人关注的. 多项研究证实了EGFR …
表皮生长因子受体酪氨酸激酶抑制剂(EGFR—TKI) 是其中最受人关注的. 多项研究证实了EGFR …
The efficacy of Kanglaite injection during treatment with tyrosine kinase inhibitor in elderly patients with non-small cell lung cancer⁎
W Zhou, T Han, Z Liu, X Yang, Y Liu… - Oncology and …, 2017 - journals.lww.com
Objective Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are
widely used in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) …
widely used in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) …